BioSpace News Archive

BeyondSpring Pharmaceuticals today announced new data highlighting the mechanism of action of plinabulin in the prevention of chemotherapy-induced neutropenia (CIN) at the 63rd American Society of Hematology (ASH) Annual Meeting and Exposition.

BioXcel Therapeutics, Inc. today announced the initiation of its pivotal Phase 3 program for BXCL501, the Company’s proprietary, orally dissolving thin film formulation of dexmedetomidine, for the acute treatment of agitation in patients with Alzheimer’s disease (AD).

Apeiron and other key shareholders enter into voluntary lock-up agreements. This voluntary lock-up extends trading restrictions by 24 months for Apeiron and 12 months for other investors.

Humacyte, Inc. today announced that results from a case study of a patient who received the human acellular vessel (HAV) as a replacement for an infected synthetic iliofemoral bypass graft.

Global biotherapeutics leader CSL Behring today announced that the Committee for Medicinal Products for Human Use (CHMP), the chief scientific body of the European Medicines Agency (EMA) accepted its request for an accelerated assessment of the etranacogene dezaparvovec Marketing Authorisation Application (MAA).

Windtree Therapeutics, Inc., a biotechnology company focused on advancing multiple late-stage interventions for acute cardiovascular and pulmonary disorders, announced that the United States Patent and Trademark Office has issued U.S. Patent No. 11197869, covering the intravenous delivery of istaroxime for the treatment of acute heart failure.

Codexis, Inc., a leading enzyme engineering company enabling the promise of synthetic biology, announced the launch of its Codex® HiTemp Reverse Transcriptase for use in one-step quantitative reverse transcription PCR.

Aerovate Therapeutics, Inc. (Nasdaq: AVTE), today announced the initiation of its Inhaled Imatinib Pulmonary Arterial Hypertension Clinical Trial (IMPAHCT) Phase 2b/Phase 3 trial to evaluate the safety and efficacy of AV-101 (dry powder inhaled imatinib) in adult patients with Pulmonary Arterial Hypertension (PAH).

Ultimovacs ASA, a clinical stage leader in immune stimulatory vaccines for cancer, announced that the first patient has been enrolled in the DOVACC study, a randomized Phase II clinical trial assessing the impact of the Company’s telomerase vaccine, UV1, on the standard of maintenance care in ovarian cancer.

BenevolentAI, a leading clinical-stage AI drug discovery company, announced that AstraZeneca has added a novel target for idiopathic pulmonary fibrosis, discovered using BenevolentAI’s platform, to its drug development portfolio.